



COLORADO CENTER FOR ANIMAL PAIN MANAGEMENT & REHABILITATION

4750 W. 120th Avenue, Suite 400, Westminster, CO 80020

FOR IMMEDIATE RELEASE
Monday, February 12, 2018

Contact: Dr. Rob Landry, 720-502-5823 www.coanimalpaincenter.com

Colorado Center for Animal Pain Management (CCAPM) is currently approved for a clinical trial for the treatment of chronic pain in dogs. In conjunction with Dr. Linda Watkins from CU Boulder Department of Psychology and Neuroscience and Xalud Pharmaceuticals, CCAPM is conducting a clinical study using a selective group of canine patients that meet the criteria for chronic pain. Several patients are suffering from chronic (long standing) debilitating and painful conditions. Several of which are maintained on a variety of pain medications to control the level of discomfort. There is a great deal of literature looking at newer and more clinically relevant means to control the transmission and perception of pain. The dynamics of pain and the complexity of the nervous system make treatment a significant challenge within both the human population as well as the veterinary population. Animals do perceive and experience several levels of pain very similar to humans. Different levels of pain can be debilitating and shorten the lives of our patients. Data supports that clinically relevant chronic pain involves the activation of glial cells. Such cells are involved with amplification of pain messages from the body to the spinal cord and from the spinal cord to the brain. Many of the medications used to manage pain have unique interactions with glial cells. By targeting glial cell activation we can decrease several pro-inflammatory substances, increase anti-inflammatory substances and finally improve the efficacy of several other medications. IL-10 is a natural protein and one of the body's anti-inflammatory substances. IL-10 has many advantages. IL-10 provides protection by stimulating tissue regeneration and regrowth, down regulates the body's pro-inflammatory substances and up regulates the body's natural anti-inflammatory substances. The delivery of IL-10 causes cells around the spinal cord to produce more IL-10. The body will not produce antibodies to the IL-10 therapy. The objective of the clinical trial is to utilize immune cells around nerves and immune-like cells within the spinal cord/central nervous system(CNS) to alter the environment and triggers that are responsible for the magnitude / degree of pain. The goal is to target the body's detrimental response to stimulus/pain by blocking several of the body's pro-inflammatory substances and promoting more of the body's anti-inflammatory properties. Targeting Glial cells along with IL-10 gene therapy will allow us to effectively approach both pain control and hopefully decrease the clinical dependence of medications as well improve efficacy of such medications. Please contact Dr. Landry at Colorado Center for Animal Pain Management to see if your family dog can benefit from this study. **There is no cost to participate in the study.**

Colorado Center For Animal Pain Management & Rehabilitation
4750 W. 120th Avenue, Suite 400
Westminster, CO 80020



IS YOUR PET IN PAIN?